by Pimwarat Srikummoon, Patrinee Traisathit, Wimrak Onchan, Chagkrit Ditsatham, Natthapat Thongsak, Nawapon Nakharutai, Salinee Thumronglaohapun, Titaporn Supasri, Phonpat Hemwan, Imjai Chitapanarux
Luminal A is the most common subtype of breast cancer and has the best prognosis comparing to the others. The association between air pollution and survival of breast cancer have been reported but not specific to this subtype. We examined pollutant distributions over a decade in upper Northern Thailand, the area of high average annual particulate matter levels, and their impact on the mortality and recurrence risks of patients with luminal A breast cancer. Retrospective data of 1,305 luminal A breast cancer patients diagnosed from 2003 to 2018 were enrolled to this study. Cox proportional hazard models were used to identify factors associated with mortality and recurrence risks including all known risk factors and the annually averaged concentrations of pollutants. On multivariable analysis; metastatic stage (adjusted hazard ratio (aHR) =10.50; 95% confidence interval (95%CI): 7.23–15.25), smoking history (aHR = 1.72; 95% CI: 1.14–2.60), and age ≥ 50 years old (aHR = 1.46; 95% CI: 1.13–1.90) were significant factors influencing mortality risk. Factors contributing to recurrence risk included metastatic stage (aHR) 4.96 (95% CI: 2.78–8.83) and exposure to the time-updated local concentration of PM10 > 55 µg/m3 (aHR = 1.68; 95% CI: 1.16–2.45). Exposure to air pollutants is one of the detrimental factors affected to recurrence and mortality in luminal A subtype breast cancer.There are estimated to be 3.4 million patients in the UK living after a diagnosis of cancer. We know very little about their quality of life or healthcare usage. Patient-reported outcome measures (PROMs) are tools which help to translate a patient’s quality of life into measurable categories, but how to do this at scale remains underexplored. The study employs a randomised design to assess different engagement strategies for optimising participation, data linkage and questionnaire completion in Northwest London and then nationally, with appropriate research approvals.
We have designed and implemented an online, patient-completed, randomised observational trial. We will pilot it in Northwest London before national roll-out, using initially the General Practice (GP) record of a cancer diagnosis and then exploring the use of social media. The primary objective is to explore the feasibility of recruiting participants via self-identification or contact from the primary care research network and obtaining consent to link participants’ PROMs responses to their cancer registry records. Data collection occurs through a secure platform, with participants directly responsible for data entry. There is no formal target sample size because this is a feasibility study, and we want to explore how many patients we can recruit. Analyses will be conducted using descriptive statistics, repeated measures multilevel modelling and machine learning techniques. If a substantial difference in responses between randomisation arms is detected, ineffective strategies will be removed. If no clear difference is observed, recruitment will continue with periodic reviews based on response rates and data completeness.
The Study Coordination Centre has obtained approval from the London—Surrey Research Ethics Committee and Health Research Authority. We will publish and disseminate the results in local, national and international meetings, in peer-reviewed journals, on social media and on websites.
It has been registered under ‘Investigating Digital Outcomes for Cancer Survivors in the Community’ (NCT06095024).
NCT06095024: Investigating Digital Outcomes for Cancer Survivors in the Community.
Stroke is the second leading cause of death worldwide, with the greatest burden in low- and middle-income countries (LMICs). Haemorrhagic stroke or spontaneous intracranial haemorrhage (sICH), including intraparenchymal haemorrhage (IPH) and subarachnoid haemorrhage (SAH), has the highest mortality and morbidity. Local management practices for haemorrhagic stroke vary greatly between geographical regions. The Planetary Outcomes after Intracranial Haemorrhage study aims to provide a global snapshot of the patient characteristics, processes of care and short-term outcomes of patients being treated for sICH across high- and low-income settings. It will also describe variation seen in care processes and available resources and time delays to receiving care. A greater understanding of the current state of sICH care is essential to identify possible interventions and targets for improved standards of care in all settings.
We describe a planned prospective, multicentre, international observational cohort study of patients admitted to hospital for management of sICH. We will include patients of all ages presenting to hospital with imaging evidence of sICH (IPH, intraventricular haemorrhage and/or SAH). The study will collect patient, care process and short-term outcome data, following patients for up to 30 days (or until discharge or death, whichever occurs first). Any centre globally where patients with sICH are admitted and managed can participate, targeting a sample size of 712 patients. The study will recruit centres worldwide through pre-existing research networks and by dissemination through neurosurgical and stroke conferences and courses. Each participating centre will complete a site questionnaire alongside patient data collection.
The study has received ethical approval by the University of Cambridge (PRE.2024.070). Participating centres will also confirm that they have undergone all necessary local governance procedures prior to starting local data collection. The findings will be disseminated via open access peer-reviewed journals, relevant conferences and other professional networks and lay channels, including the study website (https://plotich.org/) and social media channels (@plotichstudy).